t has only been 15 years since PCSK9 (proprotein convertase subtilisin/kexin type 9) was identified as an important regulator of low-density lipoprotein (LDL) metabolism. As its name suggests, PCSK9 is the ninth member of the proprotein convertase family-a group of serine proteases that are characterized by their ability to hydrolyze peptide bonds in their cognate substrates for activation.
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t has only been 15 years since PCSK9 (proprotein convertase subtilisin/kexin type 9) was identified as an important regulator of low-density lipoprotein (LDL) metabolism. As its name suggests, PCSK9 is the ninth member of the proprotein convertase family-a group of serine proteases that are characterized by their ability to hydrolyze peptide bonds in their cognate substrates for activation. 1 Initial clues were provided by a French family with familial hypercholesterolemia (FH) in 2003. 2 Abifadel et al linked gain-offunction mutations in PCSK9 with autosomal dominant hypercholesterolemia and ultimately uncovered a key new player in lipid metabolism. This seminal discovery led to a series of investigations that demonstrated that loss-offunction (LOF) mutations in PCSK9 associate with lifelong low cholesterol levels and marked reductions in the risk of atherosclerotic cardiovascular disease (ASCVD). [3] [4] [5] [6] The rare individuals with homozygous LOF mutations in PCSK9 (and no circulating protein) demonstrated extremely LDL cholesterol (LDL-C; ≈15 mg/dL), normal health and reproductive capacity, and no evidence of neurological or cognitive dysfunction. 5, 7 This complementary set of observations has been leveraged into the most important therapy for the treatment of hypercholesterolemia and ASCVD since the introduction of the statins >30 years ago. Indeed, the so-called PCSK9 inhibitors, fully human monoclonal antibodies (mAbs) that bind PCSK9, reduce LDL-C by ≈60% and risk of myocardial infarction (MI) and stroke by ≈20% after >2 years of treatment. 8 Remarkably, these agents antagonizing PCSK9 action were approved by regulatory agencies spanning the globe only a decade after its discovery. Although the scientific and medical communities have swiftly uncovered many facets of PCSK9 biology, there is still much to learn. Here, we survey the most salient aspects of PCSK9 biology and therapeutic modulation as it relates to lipoprotein metabolism, atherosclerosis, and prevention of atherosclerotic cardiovascular events.
New Player in Cholesterol Homeostasis
Much of the excitement surrounding the discovery of PCSK9 relates to revelations in lipoprotein metabolism, necessitating a reworking of models previously held for decades. In the pre-PCSK9 era, it was thought that all regulatory systems of cholesterol homeostasis were strictly intracellular, 9 with the role played by extracellular proteins limited to modulation of packaging, processing, and clearance of plasma lipoproteins. Remarkably, PCSK9 impacts lipoprotein metabolism both within (before secretion) and outside (after secretion into the circulation) of the cell. 10 Plasma cholesterol is mostly manufactured, exported, and eventually recaptured by hepatocytes. Cholesterol synthesis is a complex, multistep, and highly regulated pathway, and 3-HMG CoA-R (hydroxy-3-methylglutaryl coenzyme A reductase) is its key rate-limiting enzyme. Statins antagonize the activity of HMG CoA-R, reduce hepatic cholesterol synthesis, and upregulate the transcription of the LDLR (LDL receptor) gene via a sensing mechanism operated by the SREBP (sterol-regulatory element-binding protein) pathway. 11 Each cell in the body must maintain membrane cholesterol at a critical concentration to ensure proper membrane function. It is thus evident that the cell uses a series of regulatory and counter-regulatory steps to respond to increases and decreases in membrane cholesterol straying from the critical value range. These include synthetic, assembly, secretory, and reuptake activities. The lipid cargo, mostly triglycerides and cholesterol, is packaged within apoB (apolipoprotein leading to one of the most exciting series of discoveries in the history of medicine and the cataloging of a critical aspect of cellular life, the sensing and regulation of membrane cholesterol levels. Receptor-mediated endocytosis is facilitated by the binding of apoB on the LDL particle to the LDLR and coordinated by an adaptor protein (LDLRAP [LDL receptor adaptor protein]) that positions LDLR on the sinusoidal side of the polarized hepatocyte, clustered in coated pits. 13 The LDL/LDLR complex then gets internalized within coated vesicles and expands to join the endosomal compartment, where it eventually merges with the lysosome. The pH gradient in the descent toward the lysosome induces dissociation between receptor and cargo. In the lysosome, the LDL particle is digested, and the cholesterol and triglycerides are deesterified for transport into the cytosol, where they can take on myriad fates. On the contrary, the LDLR is recycled back to the hepatocyte surface to participate for many more rounds of LDL binding and endocytosis.
14,15 LDLR recycles every 10 minutes with a life span of 20 hours. This process allows a single LDLR to internalize hundreds of LDL particles during its life span. For decades, it was assumed that a generic ubiquitin-related sorting of altered molecules eventually terminated this recycling process. The discovery of PCSK9 heralded a new era of understanding; this low-abundance circulating protein binds cell-surface LDLR on coated pits and triggers the internalization of the receptor. The interaction between PCSK9 and LDLR locks the receptor in its open conformation in the endosome and routes the ligand-receptor pair to the lysosomal compartment for degradation, thus inhibiting the LDLR recycling that follows internalization of ligands, such as apoB on LDL and apoE (apolipoprotein E) on remnants. [16] [17] [18] [19] In other words, the normal recycling loop is short-circuited as PCSK9 disables the LDLR from escaping lysosomal digestion, thereby reducing cell-surface receptor density and resulting in raised plasma LDL-C.
It must be noted that up to half of plasma PCSK9 is associated with the LDL particle, for a frequency of 1 PCSK9 molecule for every 500 to 1000 LDL particles. 20, 21 This introduces the intriguing possibility that the carefully orchestrated cellular regulation of cholesterol concentration is ultimately under the control of a stochastic extracellular system, wherein every few hundred encounters with canonical LDL, the LDLR meets its fate by interacting with a PCSK9-carrying LDL that terminates its life cycle ( Figure 1 ).
PCSK9 Biology Structure
PCSK9 is synthesized predominantly in the liver as a 75-kDa proprotein. Based on its protein structure, [22] [23] [24] removal of the signal peptide (amino acids 1-30) produces a secreted heterodimer protein with 3 domains:
• A prodomain (amino acids and is not related to the LDLR-reducing activity of PCSK9. 25, 26 The LDLR degradation capacity of PCSK9 is based on a protein-protein interaction between the epidermal growth factor-like A domain of the LDLR and amino acids 367 to 380 in the catalytic domain region of PCSK9 independent of the proteolytic active site.
• A C-terminal domain (residues 455-692), which consists of 3 similar modules. Most of the N-terminal residues and some of the C-terminal residues are not visible in the proposed crystal structures because of poor electron density.
LDLR Degradation and PCSK9 Kinetics
The kinetics of PCSK9 binding to cell-surface LDLR exhibit Kd values that range from 90 to 840 nmol/L at neutral pH. Its affinity for the LDLR is increased by 2 orders of magnitude at lower pH with Kd values ranging from 1 to 8 nmol/L. 22, 24, 27, 28 The increased affinity at acidic pH facilitates PCSK9 capture of the LDLR in the late endosome and ensures that the PCSK9-LDLR complex will be targeted to the lysosome for degradation. 29 PCSK9 binding to LDLR occurs in 2 phases: • Rapid-phase binding accounts for one third of overall equilibrium binding and is characterized by a binding half-time of 5 to 10 minutes and half-time dissociation of 20 minutes.
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• Slow-phase binding accounts for two thirds of overall equilibrium binding and is characterized by a binding half-time of ≈1.5 hours and half-time dissociation of ≈5 hours.
Although PCSK9-LDLR binding, internalization, and lysosomal shuttling occur within 2 to 3 hours from initial contact, 31 PCSK9-mediated degradation of LDLR in vitro is only evident 12 to 24 hours after adding PCSK9 to cultured cells. 32, 33 In mice, PCSK9 remains intact in the liver for at least 4 hours after its LDLR-mediated internalization. 20 Therapeutic PCSK9 inhibition in humans only significantly reduces LDL-C levels after 2 to 3 days from start of therapy. 34 Based on these observations, it is clear that there is a delay between the first PCSK9 interaction with the LDLR and the eventual loss of LDLR. In contemplating this apparent paradox, there are several possibilities to consider. First, the PCSK9-LDLR interaction may not lead to immediate shuttling of both proteins to the lysosome for degradation and may require additional steps and interactions. Alternatively, intracellular LDLR concentrations may be in vast excess relative to cell-surface LDLR density, 35, 36 so that the initial elimination of cell-surface LDLR by PCSK9 is rapidly replenished until intracellular stores are also depleted.
On synthesis, the PCSK9 proprotein is directed to the endoplasmic reticulum by a signal sequence, subsequently removed by a signal peptidase. The proprotein form then undergoes autocatalytic cleavage, forming a heterodimer (62+13 kDa). This form is then transported to the Golgi via Figure 1 . Stochastic interaction between the LDLR (low-density lipoprotein receptor) and low-density lipoprotein (LDL)-bound PCSK9 (proprotein convertase subtilisin/kexin type 9) terminates the receptor life. Before the discovery of PCSK9, it was understood that the LDLR can recycle hundreds of times in its ≈20-h life span. Because PCSK9 is found on 1 in every 500 to 1000 LDL particles, one can envision a scenario where 1 in every 500 encounters, an LDLR binds to an LDL particle harboring a molecule of PCSK9. Such a stochastic interaction will then lead to the degradation of the receptor rather to its recycling, explaining, at least in part, why LDLR recycles hundreds of times. HDL indicates high-density lipoprotein; and Lp(a), lipoprotein(a). (Illustration credit: Ben Smith.) a COPII (coat protein/coatomer complex II) complex involving Sec24a, 37 leading to PCSK9 secretion into the blood stream. Even though PCSK9 and LDLR coexist within the secretory pathway of hepatocytes and their colocalization was suggested to result in reduced LDLR levels, it was later demonstrated that the interaction does lead to LDLR degradation. [38] [39] [40] Binding of PCSK9 to GRP94 (glucose-regulated protein 94)-an endoplasmic reticulum-resident protein expressed in hepatocytes-protects LDLR from degradation by preventing early binding of PCSK9 to LDLR within the endoplasmic reticulum. 38 Several LOF mutations in PCSK9 are known to cause impaired processing (eg, S386A), 41 trafficking (eg, R46L), 42 or secretion (eg, S462P) 43 of PCSK9, leading to low plasma PCSK9 levels and consequent hypocholesterolemia. Interestingly, some of the gain-of-function mutations of PCSK9 causing hyperlipidemia are also not secreted (eg, S127R and D129G). 42 It is possible that these mutations are able to interact with LDLR in the secretory pathway leading the complex to degradation, bypassing GRP94 protection in the endoplasmic reticulum.
Regulation of PCSK9 Levels and Function
As for all plasma proteins, PCSK9 levels represent the balance between production and clearance. Human PCSK9 is expressed in multiple tissues, with liver, small intestine, and kidney the major sources of its plasma levels. 44 The human protein shares substantial homology with its murine counterpart, with 76.6% identity. 45 The gene is found on chromosome 1 in humans and chromosome 4 in mice. PCSK9 is regulated by the SREBP through a sterol-regulatory element motif in the promoter region. 46, 47 In addition, an Sp1 motif also controls transcriptional regulation through the SREBP pathway. 48 SREBP regulation of cholesterol synthesis, LDLR, and PCSK9 results in an apparently paradoxical scenario where depletion of intracellular cholesterol levels leads to the simultaneous upregulation of both LDLR and PCSK9 expression. 48, 49 This sterol-regulatory element-mediated upregulation of PCSK9 attenuates the LDL-C-lowering effect of medications, such as statins and ezetimibe. The PCSK9 promoter also contains a hepatic nucleic factor 1 motif (between the sterol-regulatory element and Sp1 sites), which likely functions as a liver-specific regulatory sequence. [50] [51] [52] Metabolic studies in humans have shown that the production rate of PCSK9 is ≈20 µg/kg per day with a plasma pool size of ≈1000 µg. 53 Thus, given a blood pool of 5 L, the average plasma concentration of PCSK9 is ≈200 ng/mL in an average adult, and the plasma pool turns over fast, by >2 pools a day. 53 For comparison, the production rate of VLDL-apoB is 1000-fold higher (≈20 mg/kg per day). 53 At a high level, it would seem that the primary role of PCSK9 is to carry out a suicide mission that ultimately leads to the demise of the LDLR. However, careful study of PCSK9 physiology shows a less-threatening picture. PCSK9 is simply another ligand for the LDLR (just like apoB and apoE) and uses the LDLR to exit the plasma compartment. However, if PCSK9 uses LDLR as the main clearance route of elimination and at the same time it causes degradation of LDLR, then a reciprocal regulation between these 2 proteins controls plasma PCSK9 levels, hepatic LDLR expression, and plasma LDL-C levels, 20, 54 rendering the evaluation of these inextricably linked processes at any given time in the steady state extremely difficult because changes in production or efficiency in any of the 2 proteins will have consequences on the other and on LDL-C levels. In mice, plasma PCSK9 levels are highly regulated by LDLR expression. 20, 55 In mice, complete removal of the LDLR results in a substantial increase in the plasma half-life of PCSK9, 56 whereas overexpression of hepatic LDLR results in increased clearance of PCSK9. 20 Humans with homozygous or heterozygous FH manifest higher levels of plasma PCSK9 compared with non-FH controls. 54 Strangely, LDLR mutations in humans have a larger effect on LDL-C than on PCSK9 concentrations, whereas the opposite happens in mice. 57 One possible explanation is the human LDLR mutations are classified as either receptor defective or receptor negative (<2% of normal LDL internalization ability), with receptor-defective (2%-25% of normal LDL internalization ability) mutations being far more common. 58, 59 Thus, the most human LDLR mutants have some residual activity toward binding both LDL and PCSK9, whereas studies mice are done in the context of a complete absence of the LDLR.
Plasma PCSK9 can be found in 2 main forms: an intact heterodimer (62+13 kDa), which is often considered the (more) active form (stronger binding to and degradation of LDLR), and a furin-cleaved heterodimer (55+13 kDa), 60 which binds the LDLR less avidly (2-fold reduced affinity) 61 and is thus considered the less-active form. [61] [62] [63] In contrast, intracellular PCSK9 is only found in its proprotein form (75 kDa) or as an intact heterodimer ready to be secreted. 64 These findings suggest that the cleavage of PCSK9 by furin occurs outside the cell, by interaction of PCSK9 with either membrane-bound or circulating furin. Although PCSK9 and furin coexist in the Golgi, there is no clear evidence that furin is able to cleave PCSK9 intracellularly. 60 Another direct regulator of PCSK9 function in plasma is the LDL particle itself. 65, 66 It has been shown that PCSK9 associates with LDL with a K d in the range of 160 to 320 nmol/L. 67, 68 PCSK9 association with LDL is thought to occur via apoB and requires the presence of the PCSK9 prodomain. 67 We also found that plasma PCSK9 associates with lipoprotein(a; Lp[a]), although it does not bind to other apoB-containing lipoproteins, such as VLDL or chylomicrons. 69 The in vivo relevance of PCSK9 association with LDL and Lp(a) was first shown in patients undergoing lipoprotein apheresis, where together with a ≈70% reduction in LDL levels, plasma PCSK9 levels were also reduced by >50%. 70 Nevertheless, the physiological role of PCSK9 binding to lipoproteins is not clear. In vivo data suggest that the PCSK9 species associated with LDL is primarily the intact heterodimer form, whereas the non-LDL-bound (free) PCSK9 is mainly found in the furin-cleaved conformation. 70 Our in vivo and in vitro data further suggest that LDL protects PCSK9 from furin cleavage and that LDL-bound PCSK9 has a 2-fold stronger binding affinity for the LDLR compared with non-LDLbound PCSK9. 71 These observations support the notion that LDL-bound PCSK9 is the more functional form of this protein. Furthermore, the LDL-PCSK9 interaction has therapeutic potential because its modulation may lead to increased proteolytic cleavage and reduced plasma PCSK9 activity. Compartmentalization of PCSK9 and its effects on PCSK9 activity are summarized in Figure 2 .
On the contrary, it was shown that adding LDL to recombinant PCSK9 in vitro leads to reduced affinity of PCSK9 for the LDLR, likely because of competition of LDL and Figure 2 . PCSK9 (proprotein convertase subtilisin/kexin type 9) compartmentalization and function in plasma. A, PCSK9 is found in plasma in primarily 2 monomeric forms: an active form representing the full-length plasma protein and an inactive/less-active, shorter fragment, which is a cleavage product of the full-length protein by the protease furin. The active PCSK9 is found predominantly on low-density lipoprotein (LDL) and lipoprotein(a; Lp[a]) particles but not on very LDL or chylomicron remnants. In contrast, the furin-cleaved PCSK9 is not found in association with these apoB lipoproteins. Although it is not clear whether PCSK9 (active or furin cleaved) is found in association with high-density lipoprotein (HDL), it was suggested the HDL can inhibit PCSK9 function. B, PCSK9 is secreted as an active form representing the full-length plasma protein. On secretion, PCSK9 can take on 1 of 2 fates, which ultimately determines its function. (1) PCSK9 can interact with an LDL particle, which protects PCSK9 from being cleaved by furin and leaves the protein bound to the particle in its active form, or alternatively, (2) PCSK9 can interact with furin, which leads to the formation of a shorter fragment of PCSK9 that exhibits at least 2-fold lower affinity to LDLR (low-density lipoprotein receptor) with limited ability/inability to degrade it. (Illustration credit: Ben Smith.) PCSK9 for the LDLR. 67, 71 Thus, it is possible that LDL-bound PCSK9 is a physiologically less-functional fraction of plasma PCSK9. 72 The importance of defining and elucidating the factors that govern the partitioning of plasma PCSK9 and understanding the physiological role of the LDL-bound PCSK9 cannot be overstated. Experimental and translational studies will ultimately determine whether this partitioning in general, and the LDL-PCSK9 interaction in particular, can be exploited for therapeutic gains.
Receptors and Other Partner Proteins
Immediately after the discovery of LDLR-mediated degradation by PCSK9, it was found that this protein interacts with other proteins in both hepatic and extrahepatic tissues. Similar to its interaction with the LDLR, PCSK9 may engage other members of the LDLR family, such as the VLDL receptor, 10 apoER2 (apoE receptor 2), 10 and LRP1 (LDLR-related protein 1). 73 However, it is possible that PCSK9 interaction with these receptors does not lead to their degradation, or at least not in all tissues, 74, 75 and that, perhaps, its interaction with LRP1 and apoER2 leads to downstream signaling instead.
The surface scavenger receptor CD (cluster of differentiation) 36 76 and the tetraspanin receptor CD81 77 were also proposed as possible targets of PCSK9. The nature of these interactions remains unknown because these proteins do not share homology with the LDLR. CD36 is a scavenger receptor that also plays a role in muscle lipid utilization, adipose energy storage, and hepatic triglyceride storage and secretion. Thus, systemic modulation of its levels by PCSK9 may have implications on basic human physiology. CD81 plays a role in the regulation of cell development, activation, growth, and motility and also serves as an important receptor for hepatitis C virus entry to the cell.
PCSK9 has also been reported to interact with proteins other than receptors because it reduces levels of β-secretase 1 78 -an aspartic acid protease responsible for the proteolytic processing of the amyloid precursor protein-and endothelial sodium channel 79 -a membrane-bound ion channel that plays a major role in determining extracellular fluid osmolality. Amyloid-like protein 2 80 and annexin A2 81 may affect the formation and processing of the PCSK9-LDLR complex through interaction with the C-terminal domain of PCSK9. In addition, it was shown that the adrenal cells are insensitive to LDLR-mediated degradation by PCSK9 independently of annexin A2 levels. 20 HSPGs (heparan sulfate proteoglycans) play an important role in hepatic metabolism through several mechanisms, including endocytosis of lipoproteins. 82 It was recently suggested that HSPG lining the hepatocyte surface capture PCSK9 bound to the LDLR and heparin mimetics seem to have PCSK9 inhibitor activity. 82 To understand the potential role of HSPG on PCSK9, it remains to be determined whether HSPG knock down in vivo (eg, through hepatic Ndst1 [N-deacetylase and N-sulfotransferase 1] knockout 83 ) affects PCSK9-mediated LDLR degradation, PCSK9 turnover, or PCSK9 levels.
PCSK9 as a Biomarker to Predict ASCVD Risk

PCSK9 and Atherosclerosis Imaging
Because PCSK9 is a circulating protein, it could have direct effects on the plaque beyond its ability to regulate hepatic LDLR levels. Several lines of investigation have also explored the relationship between plasma PCSK9 and subclinical atherosclerosis. Chan et al 84 performed carotid intima-media wall thickness measurements in 295 asymptomatic subjects and found a significant and direct relationship between PCSK9 levels and carotid thickness. These findings corroborated earlier studies on the correlation between PCSK9 and carotid intima-media wall thickness. [85] [86] [87] However, a subanalysis of the FATE study (Firefighters and Their Endothelium) found no relationship between PCSK9 levels and measures of subclinical atherosclerosis (carotid intima-media wall thickness and flow-mediated dilation) in 1527 middle-aged men free of vascular disease. 88 The utility of serial carotid intima-media wall thickness as a means to evaluate the association of serum PCSK9 with progression of carotid plaque is limited. However, Xie et al 89 performed serial studies in 643 healthy Chinese participants from the general population as part of the Chinese Multiprovincial Cohort Study and found a statistically significant relationship between plasma PCSK9 concentration and progression of atherosclerosis as reflected by total plaque area, independent of plasma LDL-C concentration.
The coronary artery calcium (CAC) score has also been used as a means to investigate the relationship of PCSK9 to coronary atherosclerosis. Alonso et al 90 evaluated 161 genetically confirmed patients with FH who underwent CAC scoring and found that serum PCSK9 concentrations independently predicted the extent of CAC. Importantly, after full adjustment, only PCSK9 and apo(a; apolipoprotein[a]) remained predictive of CAC in this cohort of asymptomatic patients with FH. Similarly, Zhao et al 91 evaluated the association of plasma PCSK9 concentrations and CAC in 403 untreated patients presenting with chest pain and found that PCSK9 was independently associated with CAC.
The relationship of circulating PCSK9 concentration to atherosclerosis has also been explored in the context of invasive diagnostic imaging as well. Cheng et al 92 utilized intravascular ultrasound virtual histology to evaluate the association of serum PCSK9 levels and necrotic core within coronary atherosclerotic lesions in subjects with known coronary artery disease confirmed at the time of angiography. The results demonstrated a direct linear relationship between plasma PCSK9 and the necrotic core fraction in coronary plaque. Importantly, this end point remained significant in all subgroups, independent of LDL-C levels and use of statins. These observational studies cannot provide insight into the directionality of the association; thus, many questions remain. Can plasma PCSK9 influence atherogenesis through direct effect on endothelial cells or by direct transit into the subendothelial space? Does PCSK9 production within the plaque ultimately influence plasma levels? Or, is the association of these 2 factors mediated through other pathways entirely?
Epidemiological Studies
Beyond evaluations of the relationship between PCSK9 and subclinical atherosclerosis, several clinical investigations have explored PCSK9 as a biomarker of atherosclerotic risk in both primary and secondary prevention. Four major studies in primary prevention examined this issue. In the FATE study, 1527 middle-aged firefighters who were free of vascular disease at baseline were followed longitudinally for a mean of 7.2±1.7 years. 88 Although plasma PCSK9 concentration correlated with LDL-C, insulin, and triglyceride levels, it did not correlate with cardiovascular events. As a subanalysis of the Women's Health Study, Ridker et al 93 performed a nested case-control evaluation from a prospective cohort of 28 000 initially healthy American women over the age of 45 years and not on statin therapy. Plasma PCSK9 was measured at baseline among 358 cases (MI, ischemic stroke, and cardiovascular death) and 358 controls matched for age, smoking, and hormone replacement therapy (women who remained free of cardiovascular disease during 17 years of follow-up). Although there was a modest, positive association between PCSK9 level and apoB and triglycerides, no difference was seen in median PCSK9 concentrations in cases versus controls (304.4 versus 299.7 ng/mL). Moreover, baseline apoB levels predicted incident cardiovascular events but baseline PCSK9 levels did not. Leander et al 94 prospectively evaluated 4232 apparently healthy 60-year-old men and women living in Stockholm County to investigate the correlation between PCSK9 and future cardiovascular events (composite primary outcome of fatal or nonfatal MI, angina, chronic ischemic heart disease, sudden cardiac death, and fatal or nonfatal ischemic stroke). During the 15 years of follow-up, the cumulative incidence of the primary outcome was 13%. Consistent with other studies, they noted a modest relationship between plasma PCSK9 and LDL-C (r=0.18; P<0.0001) and triglyceride levels (r=0.12; P<0.0001). Unlike the study by Ridker et al, they observed a significant direct relationship between quartiles of PCSK9 concentration and incident cardiovascular events. However, incorporation of plasma PCSK9 levels into their clinical risk prediction model did not lead to significant improvement in discrimination or net reclassification-metrics that relate to clinical utility. A provocative subanalysis suggested that subjects with discordant PCSK9 and LDL-C levels (ie, high PCSK9-low LDL-C) had the highest future hazard of the primary outcome, even compared with those with high PCSK9-high LDL-C. 94 More recently, Laugsand et al 95 evaluated the use of PCSK9 as a circulating biomarker for prediction of incident MI in a nested case-control evaluation from a prospective cohort of a general population sample in Norway (1488 cases versus 3 1819 controls; 11.1 years of follow-up). Risk of MI was 47% higher in those subjects in the highest quartile of PCSK9 relative to those in the lowest quartile after adjustment for age and sex. However, when adjusting for LDL-C, the relationship no longer remained significant.
Results from secondary prevention studies are equally nondefinitive. Werner et al 96 prospectively tested whether fasting serum PCSK9 concentrations predict cardiovascular events in 504 patients with stable coronary artery disease on background statin therapy with well-controlled LDL-C levels. Although serum PCSK9 levels predicted atherosclerotic events, the association was lost when adjusting for fasting triglyceride levels. Similarly, Li et al 97 followed 616 Chinese subjects with stable coronary artery disease for 17 months to assess the relationship between PCSK9 levels and ASCVD. An association was found between PCSK9 concentrations and the severity of coronary artery disease by SYNTAX (Synergy Between PCI With TAXUS Drug-Eluting Stent and Cardiac Surgery) score. Additionally, at 17 months, cardiovascular event rates were higher in those with higher PCSK9 levels, although this relationship was noted only among those subjects who did not receive coronary revascularization. Finally, Gencer et al evaluated this issue in an acute coronary syndrome cohort. They assayed plasma PCSK9 in 2030 individuals presenting with acute coronary syndrome and undergoing coronary angiography. 98 Plasma PCSK9 levels correlated with measures of inflammation, lipid-lowering therapy, and the clinical onset of acute coronary syndrome but did not predict mortality at 1 year.
Based on the above observational trials in primary and secondary prevention, no firm conclusions on plasma measures of PCSK9 as a predictor of future cardiovascular events can be drawn. On that basis, several systematic reviews and meta-analyses have been performed in the hope of shedding further light on this relationship. [99] [100] [101] In 3 meta-analyses, when PCSK9 concentration was considered as a categorical value, the highest category of PCSK9 was associated with cardiovascular outcomes. However, when treated as a continuous variable, disparate results emerge. Part of the challenge in evaluating this issue has to do with differences in study design, clinical outcomes, and measurement methods for PCSK9. Based on the available data, clinical measurement of plasma PCSK9 for cardiovascular disease (CVD) risk prediction or for prognostic assessment is not recommended.
As discussed earlier in this review, experimental evidence demonstrates that PCSK9 is compartmentalized within the plasma, with ≈40% of PCSK9 bound to LDL and Lp(a) particles and the remainder not associated with apoB-containing lipoproteins. 20, 21, 69, 70 Given the stoichiometry between LDL and PCSK9 in plasma, approximately only 1 LDL particle in every 500 to 1000 carries at least 1 molecule of PCSK9. If, as we speculate, LDL-bound PCSK9 is biologically the more active form, future analyses should evaluate the separate association of LDL-bound and free PCSK9 with atherosclerotic events. We are currently developing a practical and reproducible assay to quantify PCSK9 in its 2 major compartments, which may elevate the status of plasma PCSK9 as a viable clinical biomarker.
Why Would PCSK9 Predict CVD Independently of LDL?
Although experimental work supports a critical role of PCSK9 in atherosclerosis, the value of circulating PCSK9 as a biomarker for ASCVD risk assessment in patients remains unclear. Because there is an inextricable link between PCSK9 and LDL-C, one would not necessarily expect plasma PCSK9 concentrations to predict risk above and beyond LDL-C unless PCSK9 has pleiotropic vascular effects.
Mendelian randomization analyses have demonstrated a common theme: genetic variants that are associated with lower LDL-C (including variants in PCSK9) also associate with a lower risk of ASCVD. 102, 103 Furthermore, the magnitude of genetically mediated LDL-C reduction relates linearly to the magnitude of ASCVD risk reduction, irrespective of the gene under study. 102, 104, 105 The results of these Mendelian randomization analyses are strikingly similar to those seen in randomized controlled clinical trials testing statins, ezetimibe, and, more recently, PCSK9 inhibitors. 8 The major difference in genetically versus pharmacologically mediated LDL-C lowering relates to a larger magnitude of risk reduction observed in the genetic analyses, given the lifetime exposure of lower LDL-C. If PCSK9, and its pharmacological inhibition, manifests clinically important pleiotropic effects on atherosclerotic events beyond LDL-C lowering, there should be differences in the magnitude of CVD risk reduction in analyses of PCSK9 variants and in the randomized controlled trials testing PCSK9 inhibitors compared with other gene variants and drugs that target LDL-C lowering. However, the perfectly consistent linear relationship between magnitude of LDL-C reduction and magnitude of ASCVD risk reduction, 106 irrespective of gene or drug, implies the theoretical pleiotropic effects of PCSK9 are likely not clinically significant.
Therapeutic Approaches to Inhibit PCSK9
and Lower Plasma Lipids
LDL Causes Atherosclerosis
The importance of atherogenic lipoproteins as the central actors in the development of ASCVD is now readily accepted. 107 The development and clinical testing of the statins with corresponding significant reductions in atherosclerotic events has been one of the great triumphs of medicine in the 20th century and has provided the key line of evidence in support of the cholesterol hypothesis. The Cholesterol Treatment Trialists' Collaborators produced an authoritative meta-analysis that included >170 000 participants in 26 randomized controlled trials testing statins. The bottom line: reducing LDL-C by 39 mg/dL yielded a 22% reduction in the risk of major vascular events and 10% reduction in allcause mortality during 5 years and independently of baseline LDL-C. 106 Despite the outstanding efficacy of the statins, we must recognize that two thirds of the expected ASCVD events in statin-treated patients cannot be prevented. In addition, additional LDL-C cholesterol-lowering interventions are needed for patients who cannot tolerate statin therapy or fail to attain adequate LDL-C lowering.
The IMPROVE-IT study (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) demonstrated that the addition of ezetimibe-a cholesterol absorption inhibitor-on top of simvastatin to patients right after an acute coronary event provided a statistically significant, although clinically modest, additional 2% absolute risk reduction in major adverse cardiovascular events, without a change in mortality. 108 Interestingly, this incremental event reduction is precisely what the Cholesterol Treatment Trialists' Collaborators meta-analysis regression line predicts, for example, the magnitude of LDL-C reduction is directly and linearly related to the magnitude of event reduction. The results of IMPROVE-IT suggest that statins are not unique in their ability to reduce ASCVD events and that LDL-C lowering is the reason for improved outcomes. The results of this trial also undid the notion of statin exceptionalism, provided the basis to pursue development of additional LDL-C-lowering agents, and ushered in the era of PCSK9 inhibitors. 109 The action of PCSK9 on LDLR can be antagonized in different ways, to include mAbs, small interfering RNAs (siRNAs), antisense oligonucleotides, adnectins, mimetic peptides, and vaccination strategies. Although small-molecule inhibitors typically are the favored first approach, their development has been challenging given the flat-surface interaction between PCSK9 and LDLR. 110 Thus far, targeting plasma (extracellular) PCSK9 with mAbs is the farthest along with 2 different fully human mAbs approved for clinical use by regulatory agencies around the world.
Therapeutic mAbs
Since 2012, many clinical trials have been performed to evaluate the LDL-C-lowering efficacy of anti-PCSK9 mAbs in subjects with different levels of CVD risk, alone or combination therapy (statin or ezetimibe), in statin-intolerant patients, and in both heterozygous and homozygous FH. The mAbs have consistently demonstrated remarkable efficacy in reducing LDL-C (≈50% as monotherapy and ≈70% reduction in combination with a statin) with a good shortterm safety and tolerability profile. 111 Thus far, 3 mAbs to PCSK9 (PCSK9 inhibitors) have been tested, with 2 of them (alirocumab and evolocumab) approved by the US Food and Drug Administration for the management of patients with either FH or ASCVD who require additional LDL-C lowering as an adjunct to diet and maximally tolerated statin therapy. Alirocumab and evolocumab are fully human antibodies and have been in the US market now for ≈3 years, whereas the third (bococizumab, now abandoned) was a humanized antibody, which retains ≈3% of murine protein sequence and for this reason induced immune responses limiting its effectiveness (neutralizing antibodies, discussed below). 112 It is interesting to note that the Food and Drug Administration approved the 2 fully human mAbs (alirocumab and evolocumab) on the basis of their LDL-C-lowering efficacy, before the results of randomized controlled cardiovascular outcome trials.
As discussed earlier, the measurement of total plasma PCSK9 concentration is not likely to be useful in risk prediction models. However, we recently proposed that measurement of total plasma PCSK9 levels in patients on PCSK9 inhibitor therapy may become useful as a diagnostic tool. 113 We demonstrated that patients treated with PCSK9 mAb exhibit an ≈7-fold increase in total plasma PCSK9 levels relative to pretreatment levels. The change in total plasma PCSK9 levels is likely because of delayed clearance of the antibody-PCSK9 complex from the circulation or because of an increase in hepatic PCSK9 production, although it is not clear at present which of these mechanisms is quantitatively more important. From a clinical perspective, the change in plasma PCSK9 levels can be used to confirm adherence to therapy or optimal injection technique in patients who do not show the expected LDL-C-lowering response to PCSK9 inhibitor therapy.
Silencing RNA
Whereas mAbs targeting PCSK9 only antagonize plasma PCSK9, siRNA interferes with its intracellular production, for example, the translation of PCSK9 mRNA to protein. The siRNA selectively and catalytically silences the translation of their complementary target mRNA in a sequence-specific manner through the formation of effector RNA-induced silencing complexes. 114, 115 A phase I trial of the siRNA against PCSK9 named inclisiran revealed similar LDL-C-lowering efficacy as the PCSK9 mAbs. 116 Interestingly, although the mAbs are dosed every 2 weeks (or once a month at a larger dose), inclisiran has a more durable effect with sustained lowering of LDL-C by an average of 53% and ≤81% at day 180, with a time-adjusted mean of >50% through day 270 after a single injection. The phase II trial of inclisiran, ORION-1 (Trial to Evaluate the Effect of ALN-PCS SC Treatment on Low-Density Lipoprotein Cholesterol), enrolled 501 subjects at high ASCVD risk with hypercholesterolemia, despite maximally tolerated statin therapy. 117 Subjects randomized to inclisiran sustained dose-dependent reductions in PCSK9 and LDL-C levels. LDL-C was reduced to the greatest extent (53%) in those who received the highest dose (two 300-mg injections) regimen of inclisiran. Changes in other plasma lipids and lipoproteins (including Lp[a] levels) with inclisiran were also similar to those seen with the anti-PCSK9 mAbs.
Inclisiran distinguishes itself from mAbs to PCSK9 in several major ways. First, its extended duration of action may hold significant advantages. Should this sustained LDL-C-lowering efficacy be realized, leveraging this therapeutic approach to PCSK9 inhibition may also help overcome issues related to medication adherence. Second, whereas the mAbs block only plasma PCSK9, the siRNA approach also reduces hepatocellular levels of PCSK9. Whether this intracellular approach has additional effects remains to be determined. Third, the lowering of plasma PCSK9 with siRNA truly reflects reduced levels of the circulating protein, which is similar to that seen in some PCSK9 LOF, whereas mAbs cause a significant accumulation of PCSK9 bound to the antibody. 113 Fourth, the siRNA approach does not affect extrahepatic production of PCSK9, 118 and thus the concentration of PCSK9 in the atheroma will be higher than for subjects treated with mAbs. Phase III studies with inclisiran are planned.
Vaccination
Vaccination represents an orthogonal approach to PCSK9 inhibition. A vaccine AT04A is in development as an agent to induce an antibody response to PCSK9. 119 In 1 study, APOE*3Leiden/CETP (cholesteryl ester transfer protein) mice vaccinated with AT04A developed elevated and persistent levels of antibody against PCSK9, with marked reductions in plasma total (−53%; P<0.001) and LDL-C levels compared with controls. 119 Additionally, biochemical measures of inflammation were significantly reduced in vaccinated animals. Total atherosclerotic lesion area was reduced by 64% (P=0.004). Interestingly, antibody concentrations remained high at the end of the study, which may translate to continued reductions in atherogenic lipoprotein concentrations for some time afterward, resulting in a long-lasting effect. A phase I study with AT04A is ongoing (NCT02508896).
More recently, another group has developed a virus-like particle PCSK9 (PCSK9Qβ-003) vaccine and tested it in both Balb/c mice and LDLR+/− mice. 120 Vaccination resulted in significant reductions in total cholesterol and plasma PCSK9 expression. Additionally, the injected animals were found to have significant upregulation of hepatic LDLR, SREBP-2, hepatocyte nuclear factor 1α, and HMG CoA-R. Positive developments in this area may lead to a viable approach to immunize humans against PCSK9, hindering the development of hypercholesterolemia and atherosclerosis. If the vaccination approach pans out, it could prove more affordable than mAbs, especially because the vaccine would be given once per year, versus once or twice a month. In addition, the vaccination strategy would have the advantage of use in younger patients and the possibility of truly preventing atheroma formation rather than stabilizing preexisting plaques. The value of lifelong exposure to low cholesterol has been proven over and over in natural randomization studies. 102, 103 Beyond these approaches to therapeutic antagonism of PCSK9, other novel methods are being pursued. Recently, a novel targetable pocket in the catalytic subunit of PCSK9 was identified. This structural identification may allow development of oral small-molecule inhibitors to antagonize the action of PCSK9. 121, 122 There is also interest in pursuing in vivo-based editing of PCSK9 using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) 123 -another approach that could have an application in younger subjects for true primary prevention purposes.
PCSK9 Inhibition: Effects on Other
Lipid Parameters
Lipoprotein(a)
Lp(a) is an atherogenic LDL-like particle with its apoB covalently bound to apo(a) by a disulfide bond. Its plasma levels are largely genetically determined. 124 Observational and genetic epidemiology data provide compelling evidence that Lp(a) has a causal role in atherosclerosis. 125 The regulation of its production and clearance is poorly understood, and no effective targeted therapies exist. Interestingly, PCSK9 inhibitors have demonstrated unexpected reductions in Lp(a), on the order of 25% to 30%. 126, 127 Although the potent reduction in LDL-C achieved by PCSK9 inhibition is mediated through its profound effect on LDLR preservation, the mechanism by which it lowers Lp(a) is unknown. Some suggest that the Lp(a) reduction achieved with PCSK9 inhibition is also secondary to the profound increase in LDLR expression, although that notion poses substantial challenges, as (1) Lp(a) is not an avid ligand for the LDLR 128 ; (2) Lp(a) metabolism in FH subjects is similar to that of non-FH subjects 129 ; (3) Lp(a) levels do not change with statin treatment, which also upregulates LDLR 130 ; (4) PCSK9 inhibition in 2 subjects with homozygous LDLR-null FH lowered Lp(a) but failed to reduce LDL-C levels 131 ; (5) LOF PCSK9 mutation carriers do not demonstrate significantly different Lp(a) levels compared with controls 3, 132, 133 ; and (6) epidemiological studies do not consistently demonstrate a correlation between plasma PCSK9 and Lp(a) concentrations. 84, 90, 93, 94, 134 On average, the lowering effect of PCSK9 inhibitors on Lp(a) is about half of that on LDL-C. The modest correlation between LDL-C and Lp(a) lowering with PCSK9 inhibition is tempered by significant discordance in the reduction of these 2 lipid fractions in ≈40% of treated individuals, who show a robust LDL-C with minimal Lp(a) response. 135 This observation suggests that PCSK9 inhibition activates alternative mechanisms beyond the LDLR and that additional factors ultimately determine the degree to which Lp(a) levels are reduced. It is likely that Lp(a) binds to and is cleared by the LDLR, at least to some extent, because its lowering by PCSK9 inhibitors is inversely related to plasma LDL-C levels. 128 Additionally, Lp(a) clearance may also be determined by the length of the apo(a) isoform. It is possible that some Lp(a) isoforms may be cleared through LRP1 136 or CD36 137 -2 receptors that are also influenced by PCSK9 inhibition. 73, 76 Other data suggest that PCSK9 does not affect Lp(a) catabolism but rather enhances apo(a) secretion and Lp(a) assembly through unknown mechanisms. 138 Potential mechanisms underlying the impact of PCSK9 inhibition on plasma Lp(a) concentration are summarized in Figure 3 .
Triglyceride-Rich Lipoproteins
Studies suggest a role for PCSK9 in triglyceride-rich lipoprotein metabolism through LDLR-mediated clearance and possibly through an effect on hepatic and intestinal apoB lipoprotein production. 66, 139, 140 Animal models have shown both LDLR-dependent and independent roles for PCSK9 on triglyceride-rich lipoprotein metabolism in the liver 141, 142 and small intestine, 143, 144 whereas individuals with the gainof-function PCSK9 mutation S127R have a 3-fold elevation in apoB100 production rates compared with noncarriers. 145 However, the effect of PCSK9 inhibition on plasma triglyceride levels is not clear because most studies only show a modest reduction that does not always reach statistical significance. [146] [147] [148] [149] [150] Although the absolute changes in triglyceride levels are similar to what is seen with statin therapy (average reduction of ≈15%), the effect of PCSK9 inhibition on triglyceride levels is dwarfed by its impact on LDL-C reduction. Metabolic studies in humans have failed to demonstrate an effect of PCSK9 inhibition on VLDL-apoB and VLDLtriglyceride production rate but show an increased fractional catabolic rate for both VLDL-apoB and VLDL-triglycerides, suggesting that PCSK9 does not impact triglyceride-rich lipoprotein production but only its clearance. 151 PCSK9 inhibition also did not influence postprandial triglyceride or apoB48 levels, consistent with the notion that PCSK9 is not directly involved in triglyceride-rich lipoprotein production in the small intestine in humans. 
High-Density Lipoprotein
Studies in mice support a direct relationship between highdensity lipoprotein (HDL) cholesterol (HDL-C) levels because as deletion of the PCSK9 gene, 152 injection of PCSK9 blocking antibodies, 153 or administration of antisense oligonucleotides against PCSK9 154 all led to reductions in HDL-C levels by 30% to 50%. In contrast, PCSK9 transgenic animals exhibit a mild increase in HDL-C levels. 20 In contrast, clinical trials with PCSK9 inhibitors demonstrate a modest (<10%) increase in HDL-C and apoAI levels. 155 The absolute changes in HDL-C levels are similar to what is observed after treatment with statins. 156 A critical difference from humans is that HDL in mice is rich in apoE, which makes it a good target for LDLR-mediated clearance. Thus, the effect of PCSK9 on HDL-C metabolism in mice is directly linked to the effect of PCSK9 on the LDLR. To date, there is no clear evidence that PCSK9 directly effects HDL production or clearance in humans. One possibility is that the rapid clearance of LDL because of PCSK9 impairs the CETP-mediated cholesterol exchange between HDL and LDL, leading to modestly increased HDL-C levels.
PCSK9 Inhibition: Clinical Outcome Studies Cardiovascular Outcomes
Before the results of the first dedicated randomized controlled cardiovascular outcome trial with PCSK9 inhibition, there were post hoc analyses of the alirocumab and evolocumab clinical trial programs that suggested that these drugs may be of significant benefit for cardiovascular event reduction. The OSLER trial (Open-Label Study of Long-Term Evaluation Against LDL Cholesterol) examined the long-term effects of evolocumab as an extension of the open-label, randomized controlled OSLER 1 and 2 trials and included 4465 patients. 157 The majority of patients (≈80%) had other cardiovascular risk factors, including hypertension, diabetes mellitus, metabolic syndrome, current cigarette use, or family history of premature coronary artery disease or of inherited hypercholesterolemia. The baseline LDL-C of 120 mg/dL was reduced by 61% to a mean of 48 mg/dL. In this post hoc analysis, the incidence of cardiovascular events (death, MI, unstable angina requiring hospitalization, coronary revascularization, stroke, transient ischemic attack, and heart failure requiring hospitalization) occurred in 1% of the evolocumab group versus 2% of the standard therapy group (hazard ratio [HR], 0.47; P=0.0003).
A similar investigation of the long-term safety, tolerability, and efficacy of alirocumab versus placebo was conducted in patients at high cardiovascular risk from the ODYSSEY LONG TERM study (Long-Term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy) of 2341 subjects. LDL-C levels were reduced by 61% in the alirocumab group to a mean of 48 mg/dL compared with an increase of 0.8% in the placebo group. The post hoc analysis of cardiovascular events (composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) again demonstrated much lower rates with alirocumab than with placebo (1.7% versus 3.3%; HR, 0.52; P=0.02). 158 It is important to realize that these studies contained few events and were not adequately powered to address cardiovascular outcomes. Regardless, many predicted that the PCSK9 mAbs would yield extraordinary outcomes in the dedicated randomized controlled trials given the magnitude and consistency of suggested cardiovascular benefit from these 2 post hoc analyses.
In the meantime, Ference et al 103 performed a Mendelian randomization analysis in an attempt to predict the results of the randomized controlled cardiovascular outcomes trials. The investigators used data from 112 772 individuals from 14 studies, with 14 120 cardiovascular events and 10 635 cases of diabetes mellitus, to categorize individuals based on inheritance of the number of LDL-lowering alleles, either variants in the genes encoding PCSK9 or HMGCR (HMG CoA reductase), the target of statins. Long-term exposure to either PCSK9 variants or HMGCR variants was associated with a remarkably similar reduction in risk of cardiovascular events per unit reduction in LDL cholesterol (by 19% per 10 mg/ dL decrease in LDL-C). In combination, the effects of these variants were additive.
Moreover, a detailed atherosclerosis imaging study reported on the impact of evolocumab on coronary plaque utilizing intravascular ultrasound. Prior intravascular ultrasound trials demonstrated statistically significant reductions in percent atheroma volume in individuals who were started on highintensity statin therapy and achieved LDL-C levels <70 mg/ dL. 159 It was not clear whether further lowering of LDL-C with PCSK9 inhibition might have more profound effects on plaque regression. The GLAGOV trial (Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound) evaluated changes in coronary atherosclerosis using serial intravascular ultrasound evaluations in subjects taking statins or statins plus evolocumab. 150 Patients with angiographic coronary artery disease on baseline statin therapy were randomized to monthly evolocumab (n=484) or placebo (n=484). A greater decrease in percent atheroma volume (1% difference) at 76 weeks was seen among those who received evolocumab. Furthermore, more patients on evolocumab than on statin experienced plaque regression (64.3% versus 47.3%; P<0.001). Several questions remained after GLAGOV: (1) will incremental plaque regression be associated with incremental cardiovascular event reduction as the prior statin monotherapy trials demonstrated, (2) if lowering LDL-C to unprecedented levels only regresses atheroma volume by 1%, have we reached the limits of what can be achieved by dramatic LDL-C lowering, and more fundamentally, (3) if attaining extreme hypocholesterolemia does not dramatically alter plaque, what other orthogonal approaches to ASCVD risk reduction need to be considered?
The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) was the first of the randomized controlled cardiovascular outcomes trials with a PCSK9 inhibitor, evolocumab. 8 The investigators randomized 27 564 patients with established ASCVD on optimized statin therapy to either evolocumab or placebo and monitored the rate of major cardiovascular events (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization in the primary outcome measure). At 48 weeks, evolocumab therapy was associated with a 59% reduction in LDL-C from a median baseline of 92 to 30 mg/dL. At a median follow-up of 26 months, evolocumab was associated with an absolute 1.5% reduction in the primary outcome, driven primarily by reductions in nonfatal MI, stroke, and revascularization. Effects of evolocumab were consistent regardless of baseline LDL-C level or intensity of background statin use. Evolocumab therapy, with its associated intense LDL-C reduction, did not decrease mortality, although the event curves between the evolocumab and placebo groups were still diverging at the time of trial termination. Although there was no overall or cardiovascular-specific mortality benefit with evolocumab, death from cardiovascular disease was remarkably low (<2%) in both groups. Interestingly, the 7-year IMPROVE-IT trial of ezetimibe added to statin therapy also did not show a reduction in mortality. 108 Other than a modest 2% incidence in injection-site reactions (which led to no excess drug discontinuations versus placebo), there was no increase in key adverse events, including new-onset diabetes mellitus or neurocognitive effects, in patients receiving evolocumab, despite the dramatic LDL-C reduction.
Did FOURIER underperform or were the post hoc analyses that preceded it simply way off? The landmark analysis presented in FOURIER demonstrated event reductions similar to those reported in years 0 to 2 of prior statin trials. 160 An enthusiastic interpretation suggests that longer duration of therapy should be associated with greater reduction in major adverse cardiovascular events and perhaps a corresponding mortality reduction. Given the significant cost of PCSK9 inhibitors and lack of established mortality benefit, their routine addition to standard-of-care statin therapy in patients with established ASCVD has thus far been reserved for those perceived to be at particularly high risk for cardiovascular events.
Subsequent analyses from FOURIER have been encouraging. One investigation assessed the efficacy and safety of evolocumab according to the degree of LDL-C reduction at 1 month. 161 The primary composite outcome declined steadily as LDL-C levels decreased, with no association between LDL-C level and adverse events. A similar reduction was observed in the key secondary end point, with 2669 subjects in the lowest LDL-C category (<20 mg/dL) at 4 weeks experiencing the lowest rate for cardiovascular death or MI (adjusted HR, 0.69; 95% confidence interval [CI], 0.56-0.85; P=0.0001) compared with the group with the highest LDL-C (>100 mg/dL). Exploratory analyses in a subgroup of 504 patients with an LDL-C <10 mg/dL showed even further reduction in cardiovascular events with no increase in safety events. Although it remains to be seen whether prolonged treatment with a PCSK9 inhibitor with profound LDL-C lowering results in mortality benefit, at the least this therapeutic approach and iatrogenic extreme hypocholesterolemia seem to be safe. In another FOURIER analysis that evaluated 22 351 subjects with a history of MI, those with recent MI, multiple prior MIs, and residual multivessel coronary artery disease had 34% to 90% greater risk for vascular events and enjoyed the greatest benefit from PCSK9 inhibition (absolute risk reduction of 2.6%-3.4% during 3 years). 162 Given the expense and barriers to access, this data may help to define appropriate allocation of PCSK9 inhibitors to those with established, high-risk ASCVD. Lastly, the FOURIER investigators evaluated the impact of evolocumab in patients with peripheral artery disease (PAD). 163 This analysis of 3642 patients with PAD demonstrated that evolocumab significantly reduced the primary composite end point. Evolocumab reduced the primary end point consistently in patients both with and without PAD, but the drop was numerically greater in patients with PAD. In patients with PAD, the absolute risk reduction on evolocumab versus placebo was 3.5% (versus 1.5% in the main FOURIER analysis) yielding an attractive number needed to treat (29) during 2.5 years. In the no-PAD group, the absolute risk reduction was only 1.4%, for a number needed to treat of 72. Interestingly, evolocumab also reduced the risk of major adverse limb events in all patients compared with placebo (HR, 0.58; 95% CI, 0.38-0.88), with consistent effects for those with and without PAD.
Bococizumab is the other PCSK9 mAb that has been evaluated in a randomized controlled cardiovascular outcome trials. In the SPIRE trials (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), participants were randomly assigned to receive either bococizumab 150 mg subcutaneously every 2 weeks or placebo. The SPIRE program included 6 parallel, multinational studies designed to assess the variability and durability of the LDL-C-lowering efficacy of bococizumab and 2 dedicated cardiovascular outcome trials. 112, 164 The lipid-lowering trials included 4300 patients on background statin therapy who were followed up for 1 year. At 12 weeks, bococizumab treatment was associated with a reduction in LDL-C levels of 55% relative to placebo. However, treatment with bococizumab often led to the development of antidrug antibodies and specific neutralizing antibodies, which attenuated the LDL-C-lowering response (48% and 29% of patients at 1 year, respectively). 164 In those who developed higher neutralizing antibody titers (upper tertile and top decile, respectively) in response to bococizumab, LDL-C concentration decreased by only 31% and 12% from baseline. Not surprisingly, given its immunogenicity, bococizumab was also associated with significantly higher rates of injection-site reactions than placebo (10.4% versus 1.3%; P<0.001).
The 2 dedicated CVOT (Cardiovascular Outcomes Trial) in the SPIRE program included a total of 27 438 patients at high risk of ASCVD (93% receiving background statin therapy) and who had either a previous cardiovascular event or history of diabetes mellitus, chronic kidney disease, PAD, or FH (high-risk, primary prevention cohort). 165 The primary end point included nonfatal MI, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, and cardiovascular death. The studies had a short duration because of the decision of the manufacturer to abandon the development of the drug. In the combined trials, those receiving bococizumab achieved the anticipated 56% mean reduction in LDL-C levels. 112 In the lower risk subject SPIRE-1 trial (baseline LDL-C, ≥70 mg/dL; median follow-up, 7 months), bococizumab did not reduce the incidence of the primary composite end point compared with placebo. In contrast, in the higher risk subject SPIRE-2 trial (baseline LDL-C, ≥100 mg/dL; median follow-up, 12 months), the rate of major cardiovascular events was significantly lowered by bococizumab (HR, 0.79; 95% CI, 0.65-0.97; P=0.02). When the SPIRE-1 and SPIRE-2 data were pooled, the incidence of the composite primary end point was not significantly different between groups (median follow-up, 10 months), although patients with the largest percentage reduction in LDL-C levels had a 25% decrease in events (HR, 0.75; 95% CI, 0.61-0.92; P=0.006), and those who had longer treatment duration (mean, 13.6 months) had a 17% reduction in events (HR, 0.83; 95% CI, 0.70-0.98; P=0.03).
Most recently, the ODYSSEY Outcomes trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome With Alirocumab) was presented at the American College of Cardiology Meeting (Presented by Dr Philippe Steg at the American College of Cardiology Annual Scientific Session, Orlando, FL, March 10, 2018). ODYSSEY Outcomes enrolled 18 924 subjects within 1 to 12 months after an index acute coronary syndrome after a run-in phase of 2 to 16 weeks on high-intensity statin therapy. Individuals who demonstrated LDL-C ≥70 mg/dL (or non-HDL-C ≥100 mg/dL or ApoB ≥80 mg/dL), despite high-intensity therapy, were randomized to alirocumab every 2 weeks or placebo. Alirocumab was titrated between 75 and 50 mg to target an LDL-C between 25 and 50 mg/dL but >15 mg/dL. The primary outcome was a composite end point, including coronary heart disease death, MI, ischemic stroke, or unstable angina. Treatment with alirocumab (on-treatment analysis) was associated with a 54.7% reduction in LDL-C and an absolute risk reduction in the primary end point of 1.6%. Of note, alirocumab was discontinued in almost 8% of the treatment group because of 2 consecutive LDL-C measurements below the prespecified threshold of 15 mg/dL. Several of the secondary outcomes favored treatment with alirocumab, although total mortality is to be considered only nominally significant given that the 2 proximal end points in the hierarchical analysis did not reach statistical significance. Nevertheless, the signal suggesting a reduction in total mortality is reassuring given that the opposite was noted in the FOURIER trial.
The 3 dedicated cardiovascular outcomes trials with therapeutic mAbs targeting PCSK9 have taught us much about what can be expected from the provision of therapeutic mAbs to high-risk patients. First, the type of antibody used to inhibit PCSK9 matters greatly. Humanized antibodies against PCSK9 are immunogenic and are associated with injectionsite reactions, the development of neutralizing antibodies, and an attenuated LDL-C lowering effect. Second, consistent with the lower is better for longer hypothesis, clinical benefits with bococizumab were greater and significant only for those patients who achieved and sustained large reductions in LDL-C. Third, although FOURIER pushed this hypothesis to lowest is best, the overall cardiovascular risk reduction afforded by the 60% reduction in LDL-C with evolocumab was modest. Fourth, and not surprisingly, the magnitude of absolute benefit is the greatest among the highest risk patients and maximized with longer exposure to drug.
Even when considering the PCSK9 mAbs in the most positive light, questions remain with regard to the cost-effectiveness of this therapeutic approach. Extrapolation of the clinical trial results reveals a number needed to treat of 74 for 2 years of treatment in FOURIER and number needed to treat of 64 during the duration of ODYSSEY Outcomes. Is this tenable for a drug that is priced at ≈$14 000 per year or almost $1 000 000 to prevent one event? This question is at the center of a debate among all stakeholders and remains unresolved.
Safety Outcomes
In early 2014, the Food and Drug Administration directed developers of PCSK9 inhibitors to monitor neurocognitive adverse effects given concerns over putative cognitive impairment because of extreme LDL-C lowering. EBBINGHAUS (Evaluating PCSK9-Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects)-a substudy of FOURIER-evaluated longitudinal neurocognitive changes in patients receiving a combination of evolocumab plus statin versus statin alone. 166 Before that, a Mendelian randomization study evaluated the association between low LDL-C and risk of dementia using genetic variation in HMGCR and PCSK9 as instrumental variables 125 and found no increased risk of dementia, Parkinson disease, or epilepsy. More recently, an analysis from REGARDS study (The Reasons for Geographic and Racial Differences in Stroke) recapitulated these findings. The investigators evaluated the association between PCSK9 LOF variants and neurocognitive impairment and decline among participants in REGARDS in study participants with (n=241) and without (n=10 454) C697X or Y142X LOF variants of PCSK9, using a comprehensive battery of neurocognitive tests. They found no differences in neurocognitive decline between the 2 groups, again suggesting that lifelong exposure to low LDL-C is not associated with cognitive dysfunction. 167 In EBBINGHAUS, a total of 1204 patients with both baseline and follow-up cognitive testing were evaluated. 157 Patient baseline characteristics were consistent with those enrolled in FOURIER, with a mean age of 63 years, 72% men and 20% with a prior stroke. Cognitive function was assessed using a standardized, well-validated computer tablet-based testing platform (Cambridge Neuropsychological Test Automated Battery), which evaluates spatial working memory strategy index of executive function (primary end point), as well as other memory assessments, including survey of everyday cognition and investigator-initiated reports of neurocognitive adverse effects. During a median follow-up of 19.8 months, there was no difference between patients in the evolocumab or placebo treatment groups, with respect to either primary or secondary end points. There was also no evidence to suggest differences in cognitive tests in patients attaining VLDL cholesterol levels, including those with levels <25 mg/dL.
More recently, a group of investigators assessed the incidence of adverse neurocognitive adverse events among participants from 14 phase II and III trials testing alirocumab. 168 Neurocognitive events were reported by 22 (0.9%) alirocumab-treated patients versus 9 (0.7%) with placebo in placebocontrolled trials (HR, 1.24; 95% CI, 0.57-2.68) and 10 (1.2%) with alirocumab versus 8 (1.3%) with ezetimibe in ezetimibecontrolled trials (HR, 0.81; 95% CI, 0.32-2.08). Rates of neurocognitive events were similar in patients with LDL-C levels <25 mg/dL (n=5/839; 0.6%; 0.5/100 patient-years) versus ≥25 mg/dL (n=26/2501; 1.0%; 0.8/100 patient-years).
Of course, the last word has not been spoken on this issue. What are the consequences of longer term therapeutic reductions in LDL-C? Besides the informative genetic analyses, it is important to bear in mind that these PCSK9 mAbs do not cross the blood-brain barrier and thus are unlikely to be associated with direct adverse effects on the central nervous system, whose lipid homeostasis is under separate regulation from the systemic one.
Another theoretical complication of PCSK9 inhibitorinduced hypocholesterolemia is diabetes mellitus. The concern of drug-induced diabetes mellitus stems from multiple lines of evidence that demonstrate that statins are associated with a modest risk of new-onset hyperglycemia, especially in patients susceptible to develop diabetes mellitus by standard markers. [169] [170] [171] Although this observation has been fairly consistent across trials, the mechanisms at play have not been elucidated. Clinical trials of PCSK9 inhibitors did not show a signal for new-onset diabetes mellitus, although these studies are of short duration. 172, 173 Two Mendelian randomization analyses provide insight on this issue as well. In one, LOF variants of PCSK9 and HMGCR were associated with increased risk of diabetes mellitus (11% and 13%, respectively). 103 In another, using data from >550 000 individuals and 51 623 type 2 diabetics, long-term exposure to LOF variants of PCSK9 associated with lower LDL-C and higher fasting glucose concentration and waist-to-hip ratio and increased risk of type 2 diabetes mellitus (odds ratio, 1.29; 95% CI, 1.11-1.50). 174 Both of these Mendelian randomization studies, therefore, suggest that, like statins, long-term treatment with a PCSK9 inhibitor may predispose vulnerable patients to increased risk of type 2 diabetes mellitus. Again, the mechanism that underpins these observations is unknown, although if this relationship is real, it may be related to upregulation of the LDLR with increased lipid uptake by the pancreatic β-cell. Although the FOURIER trial did not demonstrate an excess of diabetes mellitus in those treated with evolocumab, 8 the median duration of therapy was just for 2 years. It remains to be seen whether the Mendelian randomization analyses or the clinical trials with PCSK9 inhibitors correctly forecast the association between PCSK9 efficiency and diabetes mellitus.
Cost, Cost-Effectiveness, and Barriers to Access
The issue that has been at the center of the PCSK9 inhibitor debate relates to their cost and cost-effectiveness. With a wholesale acquisition cost of ≈$14 000 and only modest reductions in nonfatal atherosclerotic events, stakeholders have wrestled with appropriate allocation and regulations to restrict and target access to these therapies. From the time that PCSK9 mAbs received regulatory approval, payers have placed hurdles in front of patients and providers. A recent analysis identified 5 notable features of the prior authorization requirements for PCSK9 inhibitors, including (1) a requirement to submit medical records along with prior authorization forms, (2) requirements for data that may be challenging for providers to access (eg, adherence measures typically calculated from pharmacy claims and off-treatment LDL-C levels that may not be available), (3) restriction of approval to specialty prescribers (cardiologists, endocrinologists, and lipidologists), (4) requirement for genetic testing even though the same insurers will not cover the cost of testing, and (5) requirement to try multiple lipid-lowering regimens. 175 Of course, the restricted access to PCSK9 inhibitors is a complicated issue. Several cost-effectiveness analyses with these agents have been performed and demonstrate disparate results based on different modeling assumptions, although they all found that these drugs are not cost-effective at their current price. [176] [177] [178] Clearly on the basis of these analyses, the economic proposition of the therapeutic mAbs is not viable, unless only the highest risk patients are allocated to therapy. It remains to be seen whether other approaches to PCSK9 inhibition associated with longer duration of effect, such as siRNA and vaccination, may be more cost-effective.
Such barriers to access can be insurmountable for the many providers who do not have the resources to challenge an unjustified denial. In that regard, we recently presented the concept of the PCSK9 Inhibitor Clinic-a new model that streamlines and coordinates care delivery in an effort to improve approval/ access to therapy. 179 Now, with >300 patients on therapy, our rate of approval for the PCSK9 mAbs exceeds 97%. This success is because of a combination of appropriate patient selection and a comprehensive, efficient, and consistent approach to the prior authorization and appeal processes. Although this model is successful, it may not be scalable, especially in community practices. Clearly, larger efforts led by the American Heart Association and the American College of Cardiology are necessary to engender policy change at the national level.
Conclusions
The discovery of PCSK9 has ushered in an exciting new era for cholesterol management and CVD risk reduction. Fundamental biological insights have provided a far clearer understanding of lipoprotein metabolism. Based on these understandings, we are no longer limited to the previously held view that cholesterol homeostasis is an intracellular affair but rather appreciate a model whereby a secreted plasma protein, whose action can be easily inhibited, renders dominant control over lipoprotein metabolism. These findings have been translated into newly approved therapies, PCSK9 mAbs that dramatically reduce LDL-C and incrementally reduce atherosclerotic cardiovascular events, with additional therapeutic antagonists of PCSK9 likely on the way. The excitement surrounding the science and unprecedented efficiency in drug development is tempered by the practical realities of cost-effectiveness and barriers to access issues that must be resolved if the PCSK9 story is to reach its full potential. Given the prospect of PCSK9 modulators to dramatically alter approaches to cardiovascular disease prevention, all stakeholders (scientists, clinicians, guideline committees, payers, and patient advocacy groups) must work together to ensure that therapies targeting PCSK9 are appropriately evaluated, endorsed, allocated, and reimbursed.
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